Masha Sergeeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Masha Sergeeva has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed A. Samatar
Zentalis Pharmaceuticals Inc., San Diego, California
13 shared publications - Binita Chakraborty
Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina
13 shared publications - Donald Patrick McDonnell
Duke University School of Medicine, Durham, North Carolina
13 shared publications - Fernando Doñate
Zentalis Pharmaceuticals Inc., San Diego, California
13 shared publications - Jianhui Ma
Zentalis Pharmaceuticals
13 shared publications - Kevin D. Bunker
Zentalis Pharmaceuticals
13 shared publications
Latest Publications
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
Supplementary Figure S4 shows Combination of ZN-c5 and palbociclib further arrests the cells at G1 phase A. Relative ER level to DMSO after normalized to β-actin control for Figure 4B. B. MCF-7 cells were treated with 500nM of palbociclib for indicated time, cyclin D1 and p-Rb expression were examined by western blot. C. MCF-7 cells were treated with 100nM ZN-c5 or fulvestrant, 500nM palbociclib, or combination of palbociclib with ZN-c5 or fulvestrant, for 24 hours. Western blot analysis of cyclin D1, pRb, ERα and PR were performed. D. cell cycle analysis of MCF-7 cells treated with ZN-c5 or palbociclib for 48 hours.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
Supplementary Figure S4 shows Combination of ZN-c5 and palbociclib further arrests the cells at G1 phase A. Relative ER level to DMSO after normalized to β-actin control for Figure 4B. B. MCF-7 cells were treated with 500nM of palbociclib for indicated time, cyclin D1 and p-Rb expression were examined by western blot. C. MCF-7 cells were treated with 100nM ZN-c5 or fulvestrant, 500nM palbociclib, or combination of palbociclib with ZN-c5 or fulvestrant, for 24 hours. Western blot analysis of cyclin D1, pRb, ERα and PR were performed. D. cell cycle analysis of MCF-7 cells treated with ZN-c5 or palbociclib for 48 hours.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
Supplementary Table S3 shows The effect of ZN-c5 and tamoxifen on E2-induced genes
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
Supplementary Table S3 shows The effect of ZN-c5 and tamoxifen on E2-induced genes
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Data from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
Endocrine therapy has proven to be beneficial for patients with estrogen receptor (ER)–positive, HER2-negative (ER+/HER2−) breast cancer; however, de novo or acquired resistance remains a major clinical challenge. Upon progression, many of the cancers continue to be ER dependent, highlighting the opportunities for novel ER-targeting therapies. Fulvestrant, a selective ER degrader (SERD) that antagonizes and degrades ER simultaneously, has demonstrated activity in ER+/HER2− breast cancers the ability to overcome endocrine resistance. Fulvestrant has limitations, including challenging administration by intramuscular injection and poor bioavailability, resulting in suboptimal drug exposure; hence, several next-generation oral SERDs with improved drug properties have been developed and are currently being evaluated in the clinic for their therapeutic benefit. In this study, we describe the discovery of ZN-c5, an orally bioavailable SERD with favorable pharmacokinetic properties and potent activities against both wild-type and mutant ER. In vivo studies showed that ZN-c5 treatment resulted in significant tumor growth inhibition in a variety of breast cancer models and patient-derived xenograft models that harbor ESR1 mutations. Combination with CDK4/6 inhibitors or PI3K pathway inhibition enhanced antitumor effects compared with single-agent alone. ZN-c5 also demonstrated bone-protective effect as observed in a mouse osteoporosis model. These data support the clinical utility of ZN-c5 as monotherapy and as a combination therapy for patients with ER+/HER2− breast cancers. Although encouraging plasma exposure and tolerability have been observed for ZN-c5 in patients, further studies are needed to optimize its therapeutic efficacy.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
Endocrine therapy has proven to be beneficial for patients with estrogen receptor (ER)–positive, HER2-negative (ER+/HER2−) breast cancer; however, de novo or acquired resistance remains a major clinical challenge. Upon progression, many of the cancers continue to be ER dependent, highlighting the opportunities for novel ER-targeting therapies. Fulvestrant, a selective ER degrader (SERD) that antagonizes and degrades ER simultaneously, has demonstrated activity in ER+/HER2− breast cancers the ability to overcome endocrine resistance. Fulvestrant has limitations, including challenging administration by intramuscular injection and poor bioavailability, resulting in suboptimal drug exposure; hence, several next-generation oral SERDs with improved drug properties have been developed and are currently being evaluated in the clinic for their therapeutic benefit. In this study, we describe the discovery of ZN-c5, an orally bioavailable SERD with favorable pharmacokinetic properties and potent activities against both wild-type and mutant ER. In vivo studies showed that ZN-c5 treatment resulted in significant tumor growth inhibition in a variety of breast cancer models and patient-derived xenograft models that harbor ESR1 mutations. Combination with CDK4/6 inhibitors or PI3K pathway inhibition enhanced antitumor effects compared with single-agent alone. ZN-c5 also demonstrated bone-protective effect as observed in a mouse osteoporosis model. These data support the clinical utility of ZN-c5 as monotherapy and as a combination therapy for patients with ER+/HER2− breast cancers. Although encouraging plasma exposure and tolerability have been observed for ZN-c5 in patients, further studies are needed to optimize its therapeutic efficacy.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
Supplementary Table S4 shows The effect of ZN-c5 and tamoxifen on E2-suppressed genes
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
Supplementary Table S4 shows The effect of ZN-c5 and tamoxifen on E2-suppressed genes
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
Supplementary Figure S1 shows ZN-c5 is a novel SERD that inhibits growth of ER + tumors in vitro and in vivo A. ERα degradation curve after ZN-c5 treatment and DC50 (concentration at 50% degradation) determination for Figure 1B top; B. Top: western blot analysis of ERα degradation at 24 hours after fulvestrant treatment in MCF-7 cells at indicated concentration; Bottom: ERα degradation curve and DC50 determination for fulvestrant; C. Tumor growth curve of MCF-7 xenograft model. Mice bearing MCF-7 tumor cells were dosed orally once a day for 26 days. D&E, body weight changes after ZN-c5 or fulvestrant treatment.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
Supplementary Figure S1 shows ZN-c5 is a novel SERD that inhibits growth of ER + tumors in vitro and in vivo A. ERα degradation curve after ZN-c5 treatment and DC50 (concentration at 50% degradation) determination for Figure 1B top; B. Top: western blot analysis of ERα degradation at 24 hours after fulvestrant treatment in MCF-7 cells at indicated concentration; Bottom: ERα degradation curve and DC50 determination for fulvestrant; C. Tumor growth curve of MCF-7 xenograft model. Mice bearing MCF-7 tumor cells were dosed orally once a day for 26 days. D&E, body weight changes after ZN-c5 or fulvestrant treatment.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
Supplementary Figure S5 shows ZN-c5 activity in ERY537S tumors. A. Key ER downstream targets expression by qPCR in WT or ERY537S heterozygous cells. B. ER downstream target GREB expression by qPCR in WT or ERY537S heterozygous cells after treatment with 0.1nM E2, 100nM ZN-c5 or 100nM fulvestrant. C. Western blot analysis of ER and PR protein after different concentrations of ZN-c5 treatment for the indicated time in MCF7 ERY537S heterozygous cells. ER or PR protein change (%) relative to non-treatment control after correction by GAPDH. D. WHIM20 tumor bearing mice were dosed with ZN-c5 or fulvestrant at PR protein level in WHIM20 tumor samples harvested at the end of an efficacy study. ZN-c5 was dosed at 40mg/kg, fulvestrant was dosed at 5mg/dose. E. ER expression in WHIM20 tumors by immunohistochemistry (IHC) at the end of efficacy study
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
Supplementary Figure S5 shows ZN-c5 activity in ERY537S tumors. A. Key ER downstream targets expression by qPCR in WT or ERY537S heterozygous cells. B. ER downstream target GREB expression by qPCR in WT or ERY537S heterozygous cells after treatment with 0.1nM E2, 100nM ZN-c5 or 100nM fulvestrant. C. Western blot analysis of ER and PR protein after different concentrations of ZN-c5 treatment for the indicated time in MCF7 ERY537S heterozygous cells. ER or PR protein change (%) relative to non-treatment control after correction by GAPDH. D. WHIM20 tumor bearing mice were dosed with ZN-c5 or fulvestrant at PR protein level in WHIM20 tumor samples harvested at the end of an efficacy study. ZN-c5 was dosed at 40mg/kg, fulvestrant was dosed at 5mg/dose. E. ER expression in WHIM20 tumors by immunohistochemistry (IHC) at the end of efficacy study
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
Supplementary Table S5 shows Cell proliferation IC50 and maximum inhibition (Emax) in parental and ERY537S (heterozygous) after different ER ligands treatment.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
Supplementary Table S5 shows Cell proliferation IC50 and maximum inhibition (Emax) in parental and ERY537S (heterozygous) after different ER ligands treatment.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
Supplementary Table S1 shows the Representativeness of Study Participants
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
Supplementary Table S1 shows the Representativeness of Study Participants
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
Supplementary Figure S3 demonstrates ZN-c5 protects bone loss in ovariectomized mice A. Progesterone level in serum was measured after Ovariectomy (OVX) or sham surgery to confirm the success of ovariectomy. B and C. BMD in femur and tibia were monitored by InAlyzer system overtime after drug treatment. D. Micro-CT analysis of tibia microarchitecture after at the end of study (12 weeks of drug treatment). E & F. BMD measured by micro-CT in femur and tibia. G. The ratio of uterine wet weight to body weight post-mortem. Statistical significance was evaluated by 2-Way ANOVA, *P < 0.05 compared with sham vehicle. #P < 0.05, ##P < 0.01, compared with OVX-vehicle. Sham, surgery control; OVX, Bilateral ovariectomy
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
Supplementary Figure S3 demonstrates ZN-c5 protects bone loss in ovariectomized mice A. Progesterone level in serum was measured after Ovariectomy (OVX) or sham surgery to confirm the success of ovariectomy. B and C. BMD in femur and tibia were monitored by InAlyzer system overtime after drug treatment. D. Micro-CT analysis of tibia microarchitecture after at the end of study (12 weeks of drug treatment). E & F. BMD measured by micro-CT in femur and tibia. G. The ratio of uterine wet weight to body weight post-mortem. Statistical significance was evaluated by 2-Way ANOVA, *P < 0.05 compared with sham vehicle. #P < 0.05, ##P < 0.01, compared with OVX-vehicle. Sham, surgery control; OVX, Bilateral ovariectomy
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
Supplementary Table S6 shows ER and PR IHC staining average H-score
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from The Selective Estrogen Receptor Degrader ZN-c5 Has Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models
Supplementary Table S6 shows ER and PR IHC staining average H-score